宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

交易中 07-23 13:42:58

18.100

+0.480

+2.72%

最高18.150	最低17.400	成交量26.82万
今开17.420	昨收17.620	日振幅4.26%
总市值58.83亿	流通市值27.87亿	总股本3.25亿
成交额479.05万	换手率0.17%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":18.1,"timestamp":1784785367411,"preClose":17.62,"halted":0,"volume":268200,"delay":0,"changeRate":0.027241770715096505,"floatShares":154000000,"shares":325000000,"eps":-1.575354748669056,"marketStatus":"交易中","change":0.48,"latestTime":"07-23 13:42:58","open":17.42,"high":18.15,"low":17.4,"amount":4790510,"amplitude":0.042565,"askPrice":18.11,"askSize":300,"bidPrice":18.09,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-1.5556628143106925,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784794200000},"marketStatusCode":2,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":17.62,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.775074,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659","defaultTab":"news","newsList":[{"id":"2653756907","title":"宝济药业-B(02659)7月22日耗资约199.55万港元回购11.09万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653756907","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653756907?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:46","pubTimestamp":1784713609,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)公布，2026年7月22日耗资约199.55万港元回购11.09万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181823234","title":"上海宝济药业股份有限公司回购110,900股股份，涉资约199.55万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181823234","media":"公告速递","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181823234?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:46","pubTimestamp":1784713570,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年7月22日公告，发布翌日披露报表，确认当日于香港联交所场内回购110,900股H股普通股，数量占回购前公司已发行股本约0.07245%。本次回购每股价格区间介乎17.63港元至18.39港元，合计支付约199.55万港元。回购完成后，公司已发行股本由原先的153,066,450股下降至152,955,550股，同时库藏股数量增加至1,371,700股。公司表示，上述交易已严格遵守香港联交所证券上市规则及相关法律法规。本公告由执行董事刘彦君签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上海宝济药业股份有限公司回购110,900股股份，涉资约199.55万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652920332","title":"宝济药业-B(02659)7月20日斥资199.47万港元回购11.22万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652920332","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652920332?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:37","pubTimestamp":1784543826,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)发布公告，于2026年7月20日，该公司斥资199.47万港元回购11.22万股股份，每股回购价17.18-18.01港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172681805","title":"宝济药业-B回购11.22万股股份，耗资约199.47万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172681805","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172681805?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:35","pubTimestamp":1784543748,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年7月20日发布公告，宣布当日在香港联合交易所回购112,200股H股，占回购前已发行股本约0.07325%，每股购回价介乎港币17.18元至18.01元，合共付出约199.47万港元。本次回购完成后，公司已发行股本由153,178,650股降至153,066,450股，同时库藏股由1,148,600股增至1,260,800股。本次公告由执行董事刘彦君签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B回购11.22万股股份，耗资约199.47万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105212356","title":"宝济药业-B 7月17日回购11.26万股股份，耗资约199.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105212356","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105212356?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:12","pubTimestamp":1784283123,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年7月17日发布公告，披露公司在香港联交所场内回购112,600股股份，占回购前已发行股份约0.07345%。此次回购价格区间为每股港币17.43元至17.91元，合计支付约199.46万港元。回购完成后，公司已发行股份数目减少至153,178,650股，库藏股总数增至1,148,600股，已发行股份及库藏股总数维持154,327,250股。本次回购后，公司在30天内暂不进行新的股份发行或出售、转让库藏股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宝济药业-B 7月17日回购11.26万股股份，耗资约199.46万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652404491","title":"宝济药业-B(02659)7月17日斥资199.46万港元回购11.26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652404491","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652404491?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:06","pubTimestamp":1784282786,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)发布公告，于2026年7月17日，该公司斥资199.46万港元回购11.26万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120504663","title":"宝济药业-B：7月15日回购10.03万股股份，总额约199.39万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120504663","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120504663?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:02","pubTimestamp":1784109751,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年7月15日发布翌日披露报表。公告显示，公司当日在香港联交所场内回购普通股合计100,300股，约占回购前已发行股份总数的0.06539%。回购价格介乎每股19.43港元至20.12港元，合计耗资约199.39万港元。回购完成后，公司已发行股份总数为154,327,250股，其中不包括库藏股153,291,250股，库藏股为1,036,000股。公司另披露，本次回购系根据2026年5月26日通过的回购授权进行，该授权剩余可回购股份数为15,432,725股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B：7月15日回购10.03万股股份，总额约199.39万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187894933","title":"宝济药业-B 7月14日回购10.08万股股份，涉资约199.56万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187894933","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187894933?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:41","pubTimestamp":1784025665,"startTime":"0","endTime":"0","summary":"宝济药业-B于2026年7月14日公告，指公司在香港联合交易所场内回购普通股合计100,800股，占回购前公司已发行股份总数的约0.06567%。回购每股价格在每股18.78港元至20.18港元之间，总涉资约199.56万港元。公告显示，此次回购完成后，公司于2026年7月14日的已发行股份总数维持在154,327,250股，其中不包括库藏股的股份数量为153,391,550股，库藏股数量则增至935,700股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B 7月14日回购10.08万股股份，涉资约199.56万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651721621","title":"宝济药业-B(02659.HK)7月14日耗资约199.56万港元10.08万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651721621","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651721621?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:37","pubTimestamp":1784025431,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167058678","title":"宝济药业-B回购101,700股股份，耗资约199.48万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167058678","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167058678?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:25","pubTimestamp":1783938350,"startTime":"0","endTime":"0","summary":"宝济药业-B于2026年7月13日披露公告称，该公司在香港联交所场内回购101,700股H股。回购数量约占当日现有已发行股本的0.06621%，每股回购价格介乎19.20港元至20.24港元，合计耗资约199.48万港元。回购股份将作为库藏股持有。本次回购完成后，公司已发行股份总数维持在154,327,250股，其中153,492,350股为流通股份，834,900股为库藏股。公司表示，本次股份购回已获得董事会正式授权，并遵守了香港联交所主板上市规则及相关法律法规的规定。公告由执行董事刘彦君签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B回购101,700股股份，耗资约199.48万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651113501","title":"宝济药业-B(02659.HK)7月13日斥资199.48万港元回购10.17万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651113501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651113501?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:22","pubTimestamp":1783938167,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161931872","title":"宝济药业-B7月10日回购14.98万股，涉资约299.29万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161931872","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161931872?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:07","pubTimestamp":1783678027,"startTime":"0","endTime":"0","summary":"宝济药业-B于2026年7月10日在香港联交所宣布，该公司于当日回购了149,800股H股股份，约占回购前公司已发行股本0.09743%。本次回购的最高价格为每股20.08港元，最低价格为每股19.11港元，总耗资约299.29万港元。本次回购基于2026年5月26日获股东大会通过的购回授权，公司可回购股份总数为15,432,725股，截至本次回购后已累计在香港联交所及其他证券交易所回购股份733,200股，相当于授权通过当日公司已发行股本的0.47509%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B7月10日回购14.98万股，涉资约299.29万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650015189","title":"宝济药业-B(02659)7月10日斥资299.29万港元回购14.98万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650015189","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650015189?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:02","pubTimestamp":1783677775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)发布公告，于2026年7月10日斥资299.29万港元回购14.98万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650066309","title":"港股异动 | 宝济药业-B(02659.HK)盘中涨超15% BJ044有望对现有尿源提取产品形成系统性替代","url":"https://stock-news.laohu8.com/highlight/detail?id=2650066309","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650066309?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:46","pubTimestamp":1783651571,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133144370","title":"宝济药业-B：7月9日回购15.32万股，耗资约299.20万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133144370","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133144370?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:41","pubTimestamp":1783593689,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年7月9日披露翌日披露报表，宣布于当日于香港联交所场内回购普通股H股153,200股，占该公司现有已发行股份总数的约0.09955%。本次回购价格区间为每股19.07港元至19.87港元，合计支付2,992,004港元，折合约299.20万港元。据公告，宝济药业-B于2026年5月26日获股东批准可回购股份上限为15,432,725股，此前已合计回购583,400股，该数量约占购回授权获通过当日已发行股份总数的0.37803%。公告由执行董事刘彦君签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B：7月9日回购15.32万股，耗资约299.20万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650611910","title":"宝济药业-B盘中涨超6% 全球首款合成生物学重组乌司他丁BJ044获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2650611910","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650611910?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:10","pubTimestamp":1783563000,"startTime":"0","endTime":"0","summary":"　　宝济药业-B早盘一度涨超6%，截至发稿，股价上涨2.76%，报20.10港元，成交额718.87万港元。　　6月底，宝济药业宣布，自主研发的BJ044注射液临床试验申请正式获得国家药品监督管理局批准。BJ044是全球首个通过合成生物学技术开发的重组乌司他丁产品。BJ044有望凭借纯度、安全性、一致性及成本效益的全面优势，对现有尿源提取产品形成系统性替代。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-09/doc-inihence7700799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WDNA","02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650910877","title":"港股异动 | 宝济药业-B(02659.HK)早盘涨超6% 全球首款合成生物学重组乌司他丁BJ044获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2650910877","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650910877?lang=zh_cn&edition=full","pubTime":"2026-07-09 10:00","pubTimestamp":1783562438,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104823879","title":"宝济药业-B：7月8日回购14.56万股，耗资约283.58万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104823879","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104823879?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:50","pubTimestamp":1783507855,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年7月8日发布翌日披露报表，宣布于香港联合交易所回购公司股份。公告显示，本次回购股份数量为145,600股，占回购前公司已发行股本约0.09452%。回购价格区间为每股19.08港元至19.55港元，合计耗资约283.58万港元。完成回购后，公司已发行股本变更为153,897,050股，库存股份增至430,200股。公司称，本次回购基于2026年5月26日通过的购回授权，公司可根据该授权回购最多15,432,725股股份。本次公告由执行董事刘彦君签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宝济药业-B：7月8日回购14.56万股，耗资约283.58万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649960166","title":"宝济药业-B(02659)7月8日斥资283.58万港元回购14.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649960166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649960166?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:49","pubTimestamp":1783507747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B(02659)发布公告，于2026年7月8日，该公司斥资283.58万港元回购14.56万股股份，每股回购价19.08-19.55港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649496248","title":"宝济药业-B(02659)：曾俊豪已获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2649496248","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649496248?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:52","pubTimestamp":1783504346,"startTime":"0","endTime":"0","summary":"李翠女士(李女士)将继续担任另一名联席公司秘书。于方女士辞任后，曾俊豪先生(曾先生)已获委任为联席公司秘书、授权代表及法律程序代理人，自2026年7月8日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":-0.1101},{"period":"1month","weight":0},{"period":"3month","weight":-0.7899},{"period":"6month","weight":-0.8226},{"period":"1year","weight":-0.3321},{"period":"ytd","weight":-0.7728}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司是一家主要从事药品研发业务的中国公司。该公司利用合成生物技术开发及提供重组生物药物，专注于攻克治疗选择有限且药物制造工艺复杂的目标病症。该公司聚焦四大领域，包括大容量皮下给药，抗体介导的自身免疫性疾病，辅助生殖药物及以重组生物制药取代传统生化制品的变革性产品。该公司的核心产品包括SJ02（晟诺娃），是一种长效重组人卵泡刺激素羧基末端肽融合蛋白（FSH-CTP），KJ017是一种重组人透明质酸酶，以及KJ103，是一种创新重组免疫球蛋白G(IgG)降解酶。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}